

## Xeljanz (tofacitinib)Prior Authorization of Benefits Form

## **CONTAINS CONFIDENTIAL PATIENT INFORMATION**

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 844-474-3341.

1.	Pat	ient	: info	orma	tion
----	-----	------	--------	------	------

## 2. Physician information

Patient name:		Prescribing physician:			
Patient ID #:		Physician address:			
Patient DOB:		Physician phone #:			
Date of Rx:		Physician fax #:			
Patient phone #:_		Physician specialty:			
Patient email add	ress:	Physician DEA:	Physician DEA:		
		Physician NPI #:			
		Physician email address:			
3. Medication	4. Strength	5. Directions	6. Quantity per 30 days		
Xeljanz (tofacitinib)	)		Specify:		
7. Diagnosis:		,			
8. Approval criterio applicable to yo	a: (Check all boxes that appur patient and may affect t	oly. Note: Any areas not filled ou the outcome of this request.)	ut are considered not		
<ul> <li>Yes □No</li> <li>Patient has had a diagnosis of rheumatoid arthritis in the last 730 days.</li> <li>□Yes □No</li> <li>Patient has had one claim for methotrexate in the last 730 days.</li> <li>□Yes □No</li> <li>Patient has a history of inadequate response or intolerance to methotrexate.</li> <li>□Yes □No</li> <li>Patient has had one claim for a biological disease-modifying antirheumatic drug (DMARD) or potent</li> <li>immunosuppressant in the last 60 days. (PLEASE NOTE: Biological DMARD or potent immunosuppressants are: Arava, Astagraf XL, azathioprine, azulfidine, Cellcept, cyclosporine, cyclosporine modified, Gengraf, hydroxychlorquine, Imuran, leflunomide, methotrexate, mycophenolate, mycophenolic acid, Neoral, Otrexup, Plaquenil, sandimmune, sulfasalazine, tacrolimus, Trexall and Xatmep.)</li> <li>□Yes □No</li> <li>Patient has had one claim for a strong CYP3A4 inducer in the last 60 days. (PLEASE NOTE: Strong CYP3A4inducers are: Actoplus Met, Actoplus Met XR, Actos, Aptiom, Atripla, bexarotene, carbamazepine, carbamazepine ER, Carbatrol, Dilantin, Duetact, Epitol, Equetro, Intelence, Lysodren, Modafinil, Mycobutin, Mysoline, neviraprine, Orkambi, Oseni, phenobarbital, phenytek, phenytoin, pioglitazone HCL, pioglitazone-glimepiride, pioglitazone-metformin, Priftin, Primidone, Provigil, rifabutin, Rifadin, Rifamate, Rifampin, Rifater, Sustiva, Tafinlar,</li> </ul>					
	etin, Tegretol, Tracleer, Vira ent has had a serious active	Imune and Xtandi.) e infection (including hepatitis E	3 virus and/or tuberculosis) in		

Xeljanz (tofacitinib)Prior Authorization of Benefits Form Page 2 of 2

□Yes		Patient has failed a 30-day treatment trial with at least one preferred agent(s) within the				
		·				
past	80 days					
	- N.	PLEASE NOTE: The preferred agents include Enbrel and Humira.				
□Yes	□INO	Patient has a documented allergy or contraindication to preferred agents in this class.				
		PLEASE NOTE: The preferred agents include Enbrel and Humira.				
□Yes	□No	Does the client have a diagnosis of juvenile idiopathic arthritis (JIA) in the last 730 days?				
□Yes	□No	Does the client have a diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),				
rheum	atoid					
		arthritis (RA), or ulcerative colitis (UC)?				
□Yes	□No	Has the client had therapy with one or more TNF-blockers in the last 90 days?				
□Yes	□No	Patient is being treated for stage-four advanced, metastatic cancer and associated				
condit						
For the	- Texas	Medicaid Preferred Drug List, please refer to the Texas Medicaid Vendor Drug Program				
		tps://www.txvendordrug.com/formulary/formulary-search				
9. Physician signature						
7.1 11y.	siciali si	ignatore — — — — — — — — — — — — — — — — — — —				
Prescriber or authorized signature Do		authorized signature Date				
Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a						
treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the						
applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and						
necessary to the health of the patient. Note: Payment is subject to member eligibility. Authorization does not guarantee payment.						
The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This						
information is intended only for the use of the individual or entity named above. The authorized recipient of this information is						
prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the						
intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of						
	these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.					
diffulge for the retain of destroction of these documents.						